Introduction {#S1}
============

Parkinson's disease (PD) is a neurodegenerative disease that is characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) ([@B76]) and the presence of Lewy bodies (LBs) ([@B46]), in which the primary protein component is misfolded and aggregated α-synuclein (α-syn) ([@B137]). PD patients typically exhibit motor symptoms, such as tremor, stiffness, unstable posture, and slowness of movement ([@B82]), which are accompanied, and often preceded by a series of non-motor symptoms, such as intestinal dysfunction ([@B110]), sleep disorders ([@B115]; [@B34]), depression ([@B143]) and cognitive impairment ([@B138]). Among these non-motor symptoms, intestinal dysfunction has been paid special attention to, not only because it often appears prior to the motor symptoms ([@B141]), but also because α-syn aggregates have been detected in the gastrointestinal tract years before the motor-symptom onset ([@B29]; [@B139]; [@B91]; [@B98]). LBs present in the gastrointestinal tract were first described in 1986 by [@B123] in which LBs were detected in the esophagus and colon in 2 PD patients with dysphagia. Since then, more reports reinforced the discoveries of pathological α-syn in the ENS ([@B159], [@B158]; [@B17]). [@B18] postulated that LBs were first localized in the dorsal motor nucleus of the vagus (DMNV) and then spread to the upper brain regions, which inspired more researches on the time course of the presence of LBs in the gut and brain. [@B139] found that phosphorylated α-syn positive profiles were seen in 22 of 39 (56%) prodromal PD subjects and 30 of 67 (45%) prodromal tissue blocks, which were significantly higher compared to control subjects. [@B128] found that the gastrointestinal α-syn pathology precedes in the CNS at least by 6 month in human-A53T α-syn transgenic mice. These evidences consolidate the view that PD patients and animal models of PD are characterized by enteric α-syn pathology at the early stages of the disease. Therefore, it has been proposed that PD may be initiated from the gut ([@B19]).

Crohn's disease (CD) and ulcerative colitis (UC) are the two main inflammatory bowel diseases (IBD) with UC mainly affecting the colon and rectum, and CD impacting the small and large intestine ([@B6]; [@B7]). Coincidentally, IBD shares some features with PD, including a negative correlation with smoking ([@B72], [@B71]; [@B81]; [@B20]; [@B94]; [@B131]; [@B164]) and several shared risk genes, such as LRRK2 ([@B106]; [@B78]) and CARD15 ([@B10]). Interestingly, [@B41] reported the inflammatory responses in the gut since the early stages of PD, by analyzing the ascending colonic biopsies of PD patients, they found that the pro-inflammatory cytokines (TNF-α, IF-γ, IL-6, and IL-1β) and glia markers GFAP and Sox-10 were significantly elevated, and some of them (IL-6, IL-1β, and Sox-10) were negatively correlated with disease duration. [@B37] treated MYD 88 knockout mice with MPTP intraperitoneal administration, they found that MYD 88 knockout mice protected against MPTP induced TH-immunoreactive neuron degeneration in the myenteric plexus of distal ileum, although they detected no macrophage density changes compared with MPTP treated WT mice, the MYD 88 knockout mice exhibited a predominant pro-repair phenotype. Moreover, [@B38] found clear presence of M1 monocytes and increased IL-1βand IL-6 in the gut, while in the partial depletion of M1 monocytes the mice protected against MPTP induced TH expression in the gut but not in the striatum, in the meanwhile the microglia activation showed no difference in microglia activation in the brain. In addition, several studies have reported the causal relationship between IBD and PD in recent years ([@B96]; [@B55]; [@B161]; [@B181]). Here, we analyzed the recent studies on the relationship between PD and intestinal disorders, and highlighted the potential underlying mechanisms of gut inflammation triggering PD.

Relationship Between Gut Inflammation and PD {#S2}
============================================

In the earlier years, most of the findings were supportive of a relationship between PD and IBD. [@B96] demonstrated that IBD was associated with an increased incidence of PD, especially in CD, in a retrospective clinical cohort from 2000 to 2011. In a Danish nationwide cohort study (1977--2014), [@B157] also found that patients with IBD had a 22% increased risk of developing PD, compared to non-IBD individuals. However, the increased risk of PD was significantly higher in the patients with UC, but not significantly different among patients with CD. These findings were questioned by [@B165], however, after a thorough re-examination, the same conclusions were drawn ([@B156]). In contrast to these favorable reports, some studies have challenged the view on the association between PD and IBD. [@B55] identified only 2 patients with CD among 876 PD patients, which was comparable to the incidence in the general population. Moreover, PD was even inversely associated with either CD or UC, in some of the newly diagnosed PD cases ([@B24]). Although [@B166] found that IBD was associated with a higher risk of PD, the correlation appeared to be caused by a surveillance bias ([@B165]).

In a systematic review and meta-analysis, [@B161] found that IBD patients did not show increased risk of PD, however, a subgroup analysis showed a significant difference in the more aged patients (\>60 years old). [@B181] suggested that both CD and UC patients have an increased risk of PD compared to the control subjects. To date, although no consensus has been reached, among all of the researches, the most recent data implied that IBD exacerbates PD ([@B119]). However, the underlying mechanisms on how IBD could trigger PD pathogenesis are still unclear.

Evidence of Gut Inflammation Spreading to the Brain {#S3}
===================================================

As we hypothesized, gut inflammation was able to trigger PD symptoms, the three key factors, (1) the initiator from gut inflammation, (2) the pathways, and (3) the subsequent effects of gut inflammation in the brain must be analyzed step by step. In the gut the inflammatory response induces the disrupted intestinal mucosal barrier, resulting in the exposure to microbiota. Thus, the enteric nervous system, immune system, and microbiota interplayed, which is considered to be a mutually integrated interaction network ([@B174]). Then, the products or stimulation of these comprehensive interactions can spread to the brain, which may summarize as the microbiota-immune-neuro gut-brain axis. Considering that pathologic α-syn was reported as triggers of PD, we analyzed the inflammatory response and microbiota induced α-syn pathology in the gut. In addition, the inflammatory response itself was also estimated as the pathological process. Therefore, for the pathways, we will mainly introduce (1) the systemic inflammatory routes that spread proinflammatory factors and (2) the pathologic α-syn propagation pathway.

The Crosstalk Among Microbiota, Inflammatory Response and Pathological α-Syn in the Enteric Microenvironment {#S3.SS1}
------------------------------------------------------------------------------------------------------------

Although researches have demonstrated that anti-inflammatory treatment is effective to ease PD symptoms ([@B58]; [@B147], [@B146]), there is a lack of evidence of gut inflammation induced pathologic α-syn directly. However, increased inflammation in the gut, can increase gut permeability, thereby leaking intruders from the gut lumen, such as microbiota and their metabolites, may trigger aggregation of α-syn ([@B33]; [@B9]). Interestingly, the dysbiosis in PD is widely reported ([@B133]; [@B28]) and the fecal microbiota transplant is proven to ease symptoms of PD ([@B2]), suggesting an important role of microbiota in the initiation of PD. A growing body of evidence highlight the potential role of microbiota inducing pathologic α-syn ([@B53]). The first proposed mechanism is conceived from the gut lumen harbors *Escherichia coli* which can produce Curli, an extracellular bacterial amyloid protein. In a study conducted by [@B31] rats exposed to curli-producing bacteria displayed increased neuronal α-syn deposition in both gut and brain compared to rats exposed to either mutant bacteria unable to synthesize curli, or to vehicle alone. They also found that α-syn-expressing *Caenorhabditis elegans* fed on curli-producing bacteria expressed enhanced α-syn aggregation ([@B31]). The key element of Curli, CsgA, contains amyloidogenic peptide repeat motifs shared by human and yeast prions ([@B32]; [@B48]), indicating that the α-syn deposition induced by curli may result from the cross-seeding effects between with α-syn and CsgA in the gut ([@B31]). Besides, the chaperon-like proteins CsgC and CsgE encoded by the Curli operon are also found to modulate α-syn amyloid formation ([@B33]). Another mechanism is that α-syn aggregation could be induced by lipid structure in lipopolysaccharide (LPS) ([@B22]), one of the triggers of PD ([@B122]), which is mainly in the outer membrane of gram-negative bacteria. By semi-quantitative analysis using nuclear magnetic resonance (NMR), [@B22] proved that unbroken helical α-syn structure adopted an unusual, slightly unwound, α11/3 helix conformation to bind the lipid surface, indicating that α-syn can bind to the lipid structure of LPS. More substantial evidence supports this theory. [@B90] found that α-syn monomers after being incubated with LPS, showed a strong thioflavin T fluorescence. When these α-syn fibrils were injected into the striatum of mice (C57BL/6J), phosphorylated-α-syn pathology was found throughout the brains, including the striatum, SNpc, amygdala, and auditory cortex ([@B90]), demonstrating that LPS induced α-syn fibrils are toxic. Besides, in the study of [@B9] LPS was found to modulate the overall aggregation kinetics of α-syn in a concentration-dependent manner.

The microbiota is also involved in the inflammatory responses ([@B74]). It was reported that *Bacteroides fragilis*, can induce colitis through the activation of STAT3 and Th17 response ([@B168]) via the NF-κB pathway, which leads to an increase of IL-8 production by intestinal epithelial cells ([@B169]). [@B121] described that 19.3% of IBD patients with active disease have enterotoxigenic *B. fragilis* in their stool specimen, while control subjects did not show this subset of bacteria. However, the changes of *Bacteroides* in PD is still of controversy: [@B68] reported a decrease in PD patients, while [@B88] reported an increase. The inconsistent reports may result from the different stages of the patients. In a 2-year follow-up study, [@B104] reported that the deteriorated group (worsening of UPDRS I scores) had lower counts of Bifidobacterium, *B. fragilis*, than the stable group at year 0 but not at year 2. Besides, the intestinal inflammation was reported to promote the overgrowth of Enterobacteriaceae ([@B100]; [@B175]), of which the *E. coli* strains is able to induce IL-1β through NLR family pyrin domain containing 3 (NLRP3) -dependent mechanism in PD patients ([@B39]). Moreover, the Prevotellaceae that reported to be decreased in both intestinal inflammation and PD, is also involved in the inflammation. Prevotellaceae is one of main source of short chain fatty acids (SCFAs), which is reported to provide primary energy for intestinal epithelial cells to maintain the stability of the intestinal barrier, contribute to the development of colonic regulatory T (Treg) cells to limit local inflammation and engage the G protein-coupled receptor GPR43 on neutrophils to diminish their infiltration into tissues ([@B101]; [@B135]; [@B107]).

Neural Pathway of Pathologic α-Syn Spreading {#S3.SS2}
--------------------------------------------

After intensive examination of tissues from the peripheral nervous system and the brain, Braak and his colleagues proposed that the α-syn pathologies may be initiated from the olfactory system and low brain stem, which is connected to the peripheral tissues, such as the gut, via the vagal nerve. Pathological studies with postmortem tissues from the brain and the peripheral tissues suggest that pathological α-syn nucleation and aggregation may occur in the enteric neurons of the gastrointestinal tract and can propagate from the gut to the brain ([@B18]). According to this hypothesis, LBs may first be initiated in the gut ([@B17]) and then spread via the vagal nerves to the DMNV, locus coeruleus (LC), substantia nigra (SN) and cortex in sequence ([@B18]). We and others have provided direct evidence of this route ([@B73]; [@B150]). We injected a human PD brain lysate containing different forms of α-syn or different aggregated forms of recombinant α-syn into the intestinal wall of Sprague Dawley rats and found that the exogenously delivered human α-syn could be rapidly transported via the vagal nerve and reach the DMNV in the brainstem in a time-dependent manner ([@B73]). [@B150] found phosphorylated α-syn-positive LB-like aggregates in the DMNV 45 days after α-syn preformed fibrils (PFFs) were injected into the mouse gastric wall. Although these studies did not examine whether the pathological a-syn in the DMNV were of exogenous or endogenous origin, they could support a prion-like spreading of a-syn whereby α-syn replicates through a mechanism of self-propagating conformation and assembles into filaments, which can act as a seed to recruit the soluble form of the protein and enhance filament load through the seed extension ([@B59]; [@B64]). Very recently, [@B92] further reinforced the evidence for gut-to-the-brain α-syn pathology spread ([@B92]). After injecting α-syn PFFs into the muscular layer of the mouse duodenum and pylorus, the authors detected phosphorylated α-syn in DMNV, LC, SNpc and up to upper brain regions ([@B92]). More importantly they observed dopaminergic degeneration and motor and non-motor behavioral deficits in response to α-syn PFF injections in the gut ([@B92]). Vagotomy, which interrupts the spreading of α-syn PFFs from the gut the brain, alleviated the severity of morphological and behavioral alterations ([@B92]). Interestingly, no pathology was observed when the recipient mice are in α-syn knock-out background ([@B92]). This study provides strong evidence that α-syn pathology can be spread from the gut to the brain via the route of the vagal nerve, can induce neuronal degeneration, and can cause respective neuronal dysfunction and behavioral defects.

Systemic Inflammatory Routes {#S4}
============================

Not only can pathological α-syn induced by intestinal inflammation be transmitted to the brain, but also the inflammatory response itself in the gut can influence the brain. The inflammatory response in the gut may affect the brain through two routes, the neuroimmune pathway and the humoral pathway.

Neuroimmune Pathway {#S4.SS1}
-------------------

The neuroimmune pathway of gut inflammation transmitting to brain is mainly conducted by the vagal nerve. It was reported that vagotomized mice and rats presented attenuated social exploration and depression in social investigation induced by intraperitoneal injection of recombinant rat IL-1β ([@B11], [@B12]). Besides, vagal nerve stimulation could decrease the inflammatory response and improve survival in experimental sepsis, hemorrhagic shock, ischemia reperfusion injury, and other conditions of cytokine excess ([@B16]; [@B84]; [@B77]).

Up to now, the specific mechanisms of the neuroimmune pathway are not clear, but some studies have suggested that the vagal nerve plays a dual role in inflammatory regulation both through its afferent and the efferent fibers ([@B15]). The vagal afferents target the hypothalamic-pituitary-adrenal (HPA) axis. Vagal afferents activate neurons from the A2 noradrenergic group in the nucleus tractus solitarius (NTS). These neurons project to the parvo-cellular paraventricular nucleus of the hypothalamus (PVH), where the corticotrophin-releasing factor (CRF) neurons are stimulated to release CRF, which in turn induces the pituitary to release adrenocorticotropic hormone ([@B14]). Adrenocorticotropic hormone then stimulates the adrenal glands to release glucocorticoid, which plays a role in the inhibition of peripheral inflammation ([@B15]). In addition, [@B99] showed that activating cholecystokinin-1 receptors on vagal afferents can also regulate inflammation. The vagal efferents are involved in the cholinergic anti-inflammatory pathway. This pathway regulates systemic inflammation through the release of acetylcholine (Ach) by the vagal nerve ([@B176]). The details of this pathway remain obscure, but studies have showed that a subunit of the α7 nicotinic Ach receptor (α7nAchR), one of the Ach receptors, is expressed on macrophages, and the α7nAchR-agonist, GTS, is able to restrain systemic inflammation ([@B163]; [@B23]).

Humoral Pathway {#S4.SS2}
---------------

Humoral pathways of gut inflammation spreading to brain are mainly involved in the leakage of the Blood--Brain Barrier (BBB), which can be divided into disruptive and non-disruptive approaches, respectively, reflecting the physical conditions of the BBB ([@B153]).

Disruptive BBB change is usually evident in the structural alterations, and can be detected using inserted tracers ([@B153]). A considerable number of reports have shown that the BBB is damaged in PD patients ([@B120]; [@B62]). In addition, 60% of LPS induced PD models exhibited disrupted BBB ([@B153]). In the event that the blood-brain barrier is damaged, proinflammatory cytokines and immune cells such as T cells ([@B45]) and mast cells ([@B85]) from peripheral inflammation are able to enter the brain.

Non-disruptive BBB changes usually occur at a molecular level, and are not visible in histological architecture ([@B153]). The changes can be mediated by special transporters ([@B170]; [@B113]; [@B67]; [@B114]; [@B80]; [@B167]), cytokines ([@B70]; [@B134]), prostaglandins (PGs) ([@B154]) and cellular transmigration ([@B13]; [@B162]; [@B4]). In addition, substances can also enter the brain through the areas that lack the BBB, such as the circumventricular organs ([@B52]). Therefore, proinflammatory cytokines such as IL-1α, IL-1β, IL-6, TNF-α, etc., can enter the brain and activate microglia or astrocytes to induce inflammatory response ([@B152]; [@B113]; [@B132]; [@B112]).

Subsequent Effects of Gut Inflammation in the Brain {#S5}
===================================================

Pathological α-syn, which could be triggered by intestinal bacterial components, is the main component of LB, whose neurotoxicity is related to its structure and post-translational modification, such as phosphorylation at Ser129 ([@B3]) and nitration ([@B69]). These pathological proteins, on the one hand, recruit normal α-syn and disrupt its physiological functions; on the other hand, their toxicity can act as environmental stress to increase inflammation, oxidative stress, and interfere with other physiological effects ([@B171]; [@B177]). Another subsequent effect is that the immune cells and proinflammatory cytokines in the brain can cause additional release of inflammatory and neurotoxic molecules, contributing to chronic neuroinflammation and neuronal death ([@B52]; [@B149]). The underlying mechanisms of these subsequent effects inducing neurodegeneration are unclear, however, they may be involved in a series of molecular mechanisms.

It should be emphasized that the pro-inflammation and pathological α-syn propagation may not work alone, they are interrelated both in the brain and the gut. For example, marmosets with colitis show significantly increased phosphorylated α-syn in the colonic myenteric ganglia ([@B126]). In the brain, fibrillar α-syn is found to produce pro-inflammatory mediators, such as IL-1β. IL-1β via the activation of the microglial NLRP3 inflammasome ([@B35]; [@B61]). α-Syn is also found to activate pro-inflammatory TLR4 pathways in astrocytes ([@B124]) and disrupt the anti-inflammation of Dopamine D2 receptor ([@B44]). In contrast, in a study conducted by [@B75] pro-inflammatory factor S100A9 is also reported to induce α-syn aggregation.

Oxidative Stress {#S5.SS1}
----------------

Oxidative stress occurs when excessive oxygen free radicals are produced within cells. When the concentration of these active substances is not controlled by internal defense mechanisms, such as antioxidants or oxygen free radical removal enzymes, protein lipids, and DNA are oxidized causing damage ([@B57]). Studies have shown that the production of high levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS) and the reduction of antioxidant substances lead to neuronal cell death in neurodegenerative diseases ([@B49]; [@B102]).

Oxidative stress in the brain is usually found along with inflammatory responses such as activated immune cells, cytokines and other inflammatory mediators ([@B95]). These inflammatory responses activate microglia, then microglial activation with gliosis results in an oxidative burst, which releases ROS, including superoxide anion (O~2~^--^), hydrogen peroxide (H~2~O~2~), the highly reactive hydroxyl radical (HO^⋅^) and RNS such as nitric oxide (NO) into the environment ([@B149]). In addition, NO can react with O~2~^--^, producing peroxynitrite (ONOO^--^), which is a powerful oxidant and may decompose to form HO^⋅^ ([@B102]).

Pathological α-syn is also reported to be involved in causing oxidative stress in a large number of reports ([@B47]; [@B125]; [@B40]; [@B118]; [@B129]). Oxidative stress-induced toxicity depends on the structures of α-syn. [@B40] found that although both oligomeric and fibrillar α-syn can induce free radicals, only oligomeric forms of a-syn cause neurotoxicity and endogenous glutathione reduction. They also found that oligomer-induced ROS depends on the presence of metal ions, because the addition of metal chelators can block oligomer-induced ROS and reduce neuronal death ([@B40]). Interestingly, α-syn also mediates oxidative stress caused by metal ions: down-regulation of the α-syn protein significantly increases cell viability and reduced oxidative stress in maltose-aluminated cells ([@B130]). Therefore, the oxidative stress induced by metal ions or α-syn, is probably the result of the two co-factors.

Glutamate Excitotoxicity {#S5.SS2}
------------------------

Glutamate is the main cognitive neurotransmitter in the brain, inducing an excitatory response when binding to its receptors ([@B43]). In order to maintain a high signal-to-noise ratio outside the synapse, the extracellular concentration of glutamate is required to be very low. The overspill of glutamate and excessive activation of glutamate receptors can lead to neuronal dysfunction and cell death, known as excitatory toxicity ([@B43]).

Pathological α-syn has been shown to affect all of the glutamate receptors: N-methyl-D-aspartic acid (NMDA), α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) and kainic acid (KA) receptors ([@B43]). Firstly, prolonged exposure to α-syn oligomers are reported to increase basal synaptic transmission through NMDA receptor activation, triggering enhanced contribution of calcium-permeable AMPA receptors ([@B42]). Secondly, nanomolar concentrations of large α-syn oligomers, formed by incubating α-syn with organic solvent and Fe (3+) ions, altered both pre- and post-synaptic mechanisms of AMPA-receptor-mediated synaptic transmission ([@B79]). Furthermore, [@B30] found that melatonin attenuates KA-induced neurotoxicity through the reduction of KA-increased α-syn aggregation, which indicates that KA-induced neurotoxicity may be mediated by α-syn aggregation. Thus, pathological α-syn may lead to the activation of ionotropic receptors, contributing to glutamate excitotoxicity.

It has also been widely demonstrated that inflammation can induce glutamate excitatory toxicity. Firstly, monocyte-derived macrophages and activated microglia are able to induce glutamate excitotoxicity, which may result from their function of extruding glutamate into the extra synaptic space in exchange for cystine via the cystine/glutamate exchanger (Xc) -- transporter ([@B89]). Secondly, the astrocyte function of clearing, buffering and containing glutamate abilities can be decreased by inflammatory factors, such as TNF-α, IL-1β, and IF-γ ([@B66]; [@B65]). In addition, immune activation can increase glutamate-like molecular, quinolinic acid, which (1) over excites the NMDA receptor, (2) inhibits glutamine synthetase, a critical enzyme in the glutamate-glutamine cycle in astrocytes, keeping the stable glutamate level and (3) promotes glutamate release ([@B63]).

T-Cell Driven Inflammation {#S5.SS3}
--------------------------

The central nervous system was thought to be isolated from the adaptive immune system for a long period of time ([@B27]). However, [@B97] discovered the lymphatic system in the brain of mice, which were verified in monkeys and humans thereafter ([@B1]). In addition, inflammatory factors from peripheral inflammation, such as IL-1β, TNF-α can also act on the blood--brain barrier to allow peripheral lymphocytes to enter the brain.

It is well established that, T cells, especially the CD4+ T-cells, are involved in PD. [@B21] found a significant increase of T-cells but not B-cells in post-mortem brains of PD patients. Later, they identified that lacking CD4+ cells, but not CD8+ cells, led to an attenuated response to MPTP-induced dopaminergic cell death in mice ([@B21]). Additionally, [@B127] identified that the subsets of CD4+ cells, T-helper-1 (Th1) and T-helper-17 (Th17), are the main causers of MPTP-induced cell death. The mechanism by which gut inflammation causes PD through CD4+ T-cells can be seen. First of all, peptides derived from two regions of α-syn (the Tyr 39 and phosphorylated Ser129 region) can act as antigenic epitopes ([@B140]). Therefore, pathological α-syn can be captured at the lymph node, and be presented to CD4+ T-cells by antigen presenting cells (APCs) ([@B26]). If naïve CD4+ cells are activated, they transform into their subtypes: Th1 and Th17. When the BBB is damaged, Th1 and Th17 infiltrate the brain, where the microglia act as local APCs, presenting α-syn antigen via MHC II, polarizing CD4+ T-cells to the Th1 and Th17 subtypes ([@B26]). The Th1 and Th17 cells produce a large number of inflammatory factors, such as, TNF, IFN-γ, IL-1, IL-2, and IL-21 ([@B86]), which in turn re-stimulate glial cells (M1 microglia) to produce large amounts of glutamate, inflammatory factors, ROS and RNS ([@B60]), thereafter recruiting leukocytes from the blood and exaggerating more inflammatory reactions ([@B108]).

COX-2 {#S5.SS4}
-----

Cyclooxygenase-2 (COX-2), also known as prostaglandin-endoperoxide synthase 2, is one of the three cyclooxygenases (COX-1, COX-2, and COX-3) ([@B144]) that primarily induces the synthesis of prostaglandins from arachidonic acid ([@B93]). COX-2 is mainly detected in distal dendrites and dendritic spines, especially in excitatory neurons ([@B87]). In general, COX-2 is not detected in dopaminergic structures such as the SN and striatum ([@B145]). However, in PD patients and MPTP-induced mouse models, the immunopositive reaction of COX-2 in dopaminergic neurons is intense ([@B145]). Therefore, there exists a high possibility that COX-2 may be related with dopaminergic neuron death.

The mechanisms through which COX-2 damages neurons may be through two mechanisms. (1) The first one is via oxidative stress. Arachidonic acid can be converted to PGH~2~ in two steps. Firstly, arachidonic acid reacts with 2O~2~ to form the prostaglandin G~2~ (PGG~2~). Secondly, PGG~2~ is converted by the cyclooxygenases to form prostaglandin H~2~ (PGH~2~) ([@B136]). The second step of COX-2 induction reacts far more rapidly than COX-1, however, the COX-1 reaction involves the reduction of two electrons of superoxide substrate, while about 40% of the COX-2 conversion just reduces one electron of superoxide substrate ([@B144]). In this situation, the leaked electrons can react with oxygen to produce reactive oxygen species ([@B144]). (2) Another possible cause of COX-2 induced neuron death is the crosstalk between cytokines and PGs, one of COX-2's metabolized products ([@B172]). Traditionally, PGs are mostly reported to have an inhibitory effect on acute inflammation ([@B111]). However, the expression of COX-2 are widely found in chronic inflammation, such as IBD ([@B160]), rheumatoid arthritis ([@B103]; [@B83]; [@B142]; [@B50]; [@B93]), and multiple sclerosis ([@B105]). Based on this, studies found that PGs can crosstalk with cytokines and amplify the cytokines' effects. On the one hand, PGs induce expression of relevant cytokine receptors, which is typically observed in Th1 cell differentiation and Th17 cell expansion ([@B173]); on the other hand, PGs and cytokines synergistically activate NF-κB to induce expression of inflammation-related genes, including chemokines and COX-2 itself ([@B172]). These signals amplify chronic immune inflammation and exacerbate

neuronal death. In addition, the overexpression of COX-2 in dopaminergic neurons also plays a role in α-syn accumulation ([@B5]).

The Reaction of Central Neuroinflammation in Gut {#S6}
================================================

Among the various pre-clinic PD animal models, the intranigral injections of 6-OHDA or LPS directly act on the nigra-striatal system, thus, they could be used to elucidate the effect of nigral-striatal degeneration on the gut, comparing to the peripheral administration which may affect the gut first or at the same time. In the 6-OHDA induced PD model, gastrointestinal dysfunctions have widely been reported (see [Table 1](#T1){ref-type="table"}), such as delayed gastric empty ([@B179], [@B178]; [@B148]; [@B155]; [@B51]), impaired gastric motility ([@B179], [@B178]; [@B155]; [@B51]), impaired colonic transit ([@B54]; [@B116]), decreased weight and water content of the feces ([@B182]), colonic relaxation defect ([@B36]), decreased intraluminal pressure ([@B36]), decreased frequency of peristalsis ([@B36]). In addition, in the studies of Pellegrini et al., inflammatory evidence is also presented in the model of intranigral injection of 6-OHDA, such as the increased GFAP, TNFα, IL-1β, eosinophils and mast cell in colon. In addition, in the study of intranigral injection of LPS, the impaired gastric motility is also observed. Further, in a study conducted by [@B151] the pathological α-syn was transported from the brain to the stomach. Therefore, the central neuroinflammation and nigrostriatal degeneration could, in turn, spread to the ENS and contribute to exacerbated intestinal inflammatory responses and gastrointestinal dysfunction via brain-to-the-gut descending pathways, thus generating a positive loop that could drive the chronicization of the ongoing central and peripheral neuroinflammatory and neurodegenerative processes and contribute to gut motor dysfunctions.

###### 

Summary of intestinal function and inflammatory alterations in Parkinson's disease (PD) animal models of intranigral injection of 6-OHDA or LPS.

  **Model (species)**                                **Functional evidence**                                                                          **Inflammatory evidence**                                                               **References**
  -------------------------------------------------- ------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------- ----------------
  Bilateral intranigral injection of 6-OHDA (rat)    Delayed gastric empty; Impaired gastric motility;                                                                                                                                        [@B179]
                                                     Delayed gastric empty; Impaired gastric motility;                                                                                                                                        [@B178]
                                                     Delayed gastric empty and intestinal transport; decreased fecal pellets and content                                                                                                      [@B51]
  Unilateral intranigral injection of 6-ohda (rat)   Delayed gastric empty;                                                                                                                                                                   [@B148]
                                                     Delayed gastric empty; Constipation                                                                                                                                                      [@B155]
                                                     Decreased weigh and water Content of fecal matter;                                                                                                                                       [@B182]
                                                     Impaired colonic transit;                                                                                                                                                                [@B54]
                                                     Impaired colonic transit;                                                                        GFAP↑(colon); TNF-α↑(colon); IL-1β↑(colon); Eosinophils↑ (colon); Mast cells↑ (colon)   [@B116]
                                                     Colonic relaxation defect; Decreased intraluminal pressure; Decreased frequency of peristalsis                                                                                           [@B36]
                                                                                                                                                      TNF↑ (colon); IL-1β↑ (colon); Eosinophils↑ (colon); Mast cells↑ (colon)                 [@B117]
  Bilateral intranigral injection of LPS (rat)       Impaired gastric motility                                                                                                                                                                [@B180]

Conclusion {#S7}
==========

Based on the analyses above, we summarize the potential association of intestinal inflammation in PD pathogenesis, as shown in [Figure 1](#F1){ref-type="fig"}. Increased intestinal permeability caused by gut inflammation induces the leakage of flora and its metabolites into the body ([@B8]; [@B25]; [@B109]), stimulating the production of pathologic α-syn or pro-inflammatory cytokines ([@B31]; [@B90]; [@B56]). Pathologic α-syn can be spread to the brain via the vagal nerve and pro-inflammatory cytokines and immune cells transmit to the brain through the humoral system. In addition, the leakage of flora and its metabolites from gut lumen can also activate immune cells, such as T cells. These immune cells can infiltrate into the brain via the disrupted BBB caused by the pro-inflammatory cytokines. In the brain, the two factors, pathologic α-syn and pro-inflammatory cytokines and immune cells enhance the dysfunction and degeneration of dopaminergic neurons. They, together with tissue debris or diseased proteins released from lysed cells, trigger the cascade and feedback loop of inflammation, including microglial activation, and neuronal dysfunction and cell death.

![Possible pathways involved in gut inflammation induced neuron death in the brain. Gut inflammation may increase intestinal permeability, allowing the leakage of bacteria and their metabolites which may trigger pathologic α-syn aggregation and pro-inflammatory cytokine production and release in the ENS. Pathologic α-syn is propagated to the brain via the vagal nerve, and inflammatory cytokines are transported to the brain through the humoral pathway or stimulate the vagal nerve to produce pro-inflammatory factors in the brain. Pro-inflammatory cytokines and synucleinopathies in the brain may induce neuronal injury and death, which in turn enhance more severe inflammatory responses.](fnmol-12-00218-g001){#F1}

Of note, although a large body of evidence has implied the relationship between PD and gut inflammation, details on how the process takes place are still largely unknown. Further investigations are required to clarify the mechanisms of the mutual transformation between intestinal inflammation, microbiota and pathological α-syn or other PD-related pathogens.

Overall, we have briefly addressed the mechanisms on how gut inflammation is transmitted to the brain and how it causes damage in the brain. We hope that this will provide some clues for further studies in this interesting field of research.
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